mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials

We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free surviva...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncotarget
Main Authors: Rotundo, Maria Saveria, Galeano, Teresa, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2016
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053632/
https://ncbi.nlm.nih.gov/pubmed/26895472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7446
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍